Healthcare / Drug Manufacturers - Specialty & GenericKSE
$76600.00
-900.00 (-1.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.8B · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.01T
P/E
13.1x
↓EV/EBITDA
8.8x
↓ROE
7.7%
↑Gross Margin
31.1%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.4%
FCF CAGR
—
FCF margin
-6.6%
FCF / Net income
-1.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.69T · net income $77.51B · FCF $-111.77B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1692.40B | $1692.40B | $1586.43B | $1669.40B | $1488.34B |
| Net Income | $77.51B | $77.51B | $109.07B | $212.52B | $80.95B |
| EBITDA | $133.15B | $133.15B | $150.10B | $287.90B | $137.61B |
| EPS | 5846.00 | 5846.00 | 8234.00 | 14485.71 | 5726.98 |
| Gross Margin | 31.1% | 31.1% | 33.6% | 39.7% | 36.5% |
| Operating Margin | 4.8% | 4.8% | 6.3% | 14.8% | 7.4% |
| Net Margin | 4.6% | 4.6% | 6.9% | 12.7% | 5.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.21 | 0.27 | 0.38 |
| Current Ratio | 1.72 | 1.72 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-111.77B | $-111.77B | $-1.81B | $249.35B | $14.67B |
| Returns | |||||
| ROE | 7.7% | 7.7% | 12.2% | 26.1% | 13.0% |
| Valuation | |||||
| P/E | 13.10 | 13.10 | 10.88 | 8.23 | 12.89 |
| EV/EBITDA | 8.77 | 8.77 | 7.64 | 6.08 | 8.44 |
| P/B | 1.01 | 1.01 | 1.33 | 2.14 | 1.68 |
| Growth & Yield | |||||
| Revenue Growth | 6.7% | 6.7% | -5.0% | 12.2% | — |
| EPS Growth | -29.0% | -29.0% | -43.2% | 152.9% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.2%
EPS terminal req.
$6796.97
Spread vs growth
-34.2%
5Y implied EPS CAGR
7.1%
EPS terminal req.
$8224.34
Spread vs growth
-36.1%
10Y implied EPS CAGR
8.5%
EPS terminal req.
$13245.38
Spread vs growth
-37.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.0%
Start / end P/E
9.7x → 13.1x
EPS bridge
8234.00 → 5846.00
Residual
-10.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.